Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Trading Statement

23 Mar 2009 07:00

RNS Number : 2116P
ViaLogy PLC
23 March 2009
Β 

ο»Ώ

VIALOGYΒ PLCΒ ("VIALOGY" OR "THE COMPANY")Β 

VIALOGY TECHNOLOGY DELIVERS LARGEΒ OILΒ FIND

Β 

LONDON,Β March 23rd, 2009Β - ViaLogyΒ PLCΒ (LSE: VIY).Β ViaLogy announces today that its QuantumRDβ„’ oil exploration technology and service has been credited with locating a major new oil deposit on the Galba Prospect in South Central Texas. The success marks the operational and commercial validation of ViaLogy's software-based seismic interpretation service for oil and gas reservoir discovery and characterization. The technology accurately predicted the size, location and porosity of three reservoirs.Β 

The successful drilling effort and oil strike based on the ViaLogy analysis located reservoirs at increasing depths estimated to contain a total of over 2 million barrels of recoverable reserves.Β ViaLogy's contract with Atascosa Exploration LLC, ofΒ San Antonio,Β Texas, for the Galba Prospect foresees multiple wells on the lease, now determined to be 4 or 5, targeted at the three reservoirs and positioned by ViaLogy. The first well, just completed, has located a reservoir with an estimated oil deposit which will produce 153,000 barrels of crude oil (i.e. 35% primary recovery based on an overall actual volume of 460,000 barrels). Atascosa plans extractions of 50% of the recoverable reserves in first three years. Under its contract with Atascosa, ViaLogy will receive a 5% Back-In-After-Payout (BIAPO) working interest. This means that after costs ViaLogy will receive over $300KΒ duringΒ the life of this first well (assuming oil price at $40 per barrel). Galba Prospect production will begin immediately. For the entire field, ViaLogy could receive 5% of the 2 million barrels over the lifetime of the field's wells which, assuming an average $40 oil price, would produce around $4 million.

ViaLogy's role in the Galba Prospect project included the design and acquisition of new, high-resolution 3D seismic survey data, integrated geoseismic and geological assessment, and positioning of the drill site. ViaLogy collaborated closely with Atascosa's geology and production team. Oil was found at the depth and with the porosity ViaLogy predicted in the Upper Wilcox formation, and all other parameters conformed toΒ ViaLogy's analysis and its determination of coordinates for the drilling site.

ViaLogy believes that its geoseismic interpretation technology will address a problem faced by the oil industry worldwide - to avoid drilling dry holes. InΒ Texas, only four out of 10 exploratory wells, including those drilled with the aid of seismic, find oil or gas in economically producible quantities. Abortive attempts are costly. According to US Dept. of Energy (DOE) Energy Information Administration (EIA) statistics, the 2006 average cost for drilling an on-shore dry hole in theΒ USΒ was over $450,000. The success of the Galba Project reinforces QuantumRD's value proposition for locating oil reservoirs while lowering the probability of dry holes, and thus reducing the overall cost of exploration.Β 

Working with Atascosa, ViaLogy plans to market the QuantumRD technology and service initially to US independent exploration companies. QuantumRD is a computational technology based on ViaLogy's patented QuantumΒ Resonance Interferometry (QRIβ„’), an active signal processing technique capableΒ of significantly increasing the signal to noise ratio of seismic data and improving its value.

Commenting on the Galba Prospect find, Atascosa's Chief Executive, John Mullins, said: "We're very pleased with the success of this well. We have increased our lease positions at the prospect, and are planning to further grow our collaboration with ViaLogy on Galba and other prospects. Our geology team has been working with the ViaLogy scientists for some months now, and we're highly impressed with the technology behind QuantumRD. The accuracy of the results is remarkable and the payoff is reducing the risk of dry holes."

He added, "The quality of the information relating to the size and content of the reservoirs enables us to position the wells to extract the maximum amount of hydrocarbons."

ViaLogy's CEO, Robert W. Dean, commented: "Our success inΒ TexasΒ validates QuantumRD, and is a key step in building a services business in the oil and gas industry. We have a potentially global product, but initially we intend to focus our sales efforts for our oil detection technology and services on US-based independent exploration companies. Going forward, we expect it will be attractive to established seismic data companies, oil field services companies, and the oil majors."

For further information please contact:

ViaLogy

Robert W Dean, President & CEO -Β USΒ +1 626-296-6337 (mobile: +1 703-589-3807) Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756)

Atascosa Exploration LLCΒ Β  John D. Mullins, CEO (+1 210-402-3656)Β 

Nominated Advisor (SeymourΒ Pierce)Β Β  Mark Percy +44 (0) 20-7107-8000Β 

Brokers to ViaLogyΒ PLCΒ 

Sebastian Wykeham, St. Helen's Capital - +44 (0) 7628 5582Β 

About ViaLogy: Network Centric Signal ProcessingΒ Β  ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noiseΒ background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website atΒ www.ViaLogy.com.Β 

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied.


This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTPUURWWUPBGGU
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.